Abstract:The objectives of the present study were to investigate the effect of ANG-(1-7) on the development of cardiac hypertrophy and to identify the intracellular mechanism underlying this action of ANG-(1-7). Blood pressure and heart rate were recorded using radiotelemetry before and after chronic subcutaneous infusion of control (PBS), ANG II, ANG-(1-7), or ANG II + ANG-(1-7) for 4 wk in normotensive rats. Chronic administration of ANG-(1-7) did not affect either basal blood pressure or the ANG II-induced elevation in blood pressure. However, ANG-(1-7) significantly attenuated ANG II-induced cardiac hypertrophy and perivascular fibrosis in these rats. These effects of ANG-(1-7) were confirmed in cultured cardiomyocytes, in which ANG-(1-7) significantly attenuated ANG II-induced increases in cell size. This protective effect of ANG-(1-7) was significantly attenuated by pretreatment with A779 (a Mas receptor antagonist) or Mito-TEMPO (a mitochondria-targeting superoxide scavenger) as well as blockade of Sirt3 (a deacetylation-acting protein) by viral vector-mediated overexpression of sirtuin (Sirt)3 short hairpin (sh)RNA. Western blot analysis demonstrated that treatment with ANG-(1-7) dramatically increased Sirt3 expression. In addition, ANG-(1-7) attenuated the ANG II-induced increase in mitochondrial ROS generation, an effect that was abolished by A779 or Sirt3 shRNA. Moreover, ANG-(1-7) increased FoxO3a deacetylation and SOD2 expression, and these effects were blocked by Sirt3 shRNA. In summary, the protective effects of ANG-(1-7) on ANG II-induced cardiac hypertrophy and increased mitochondrial ROS production are mediated by elevated SOD2 expression via stimulation of Sirt3-dependent deacetylation of FoxO3a in cardiomyocytes. Thus, activation of the ANG-(1-7)/Sirt3 signaling pathway could be a novel therapeutic strategy in the management of cardiac hypertrophy and associated complications.NEW & NOTEWORTHY Chronic subcutaneous ANG-(1-7) has no effect on ANG II-induced elevations in blood pressure but significantly attenuates ANG II-induced cardiac hypertrophy and fibrosis by a mitochondrial ROS-dependent mechanism. This protective effect of ANG-(1-7) against the action of ANG II action is mediated by stimulation of sirtuin-3-mediated deacetylation of FoxO3a, which triggers SOD2 expression.

Downregulation of Amphiregulin Improves Cardiac Hypertrophy Via Attenuating Oxidative Stress and Apoptosis

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

Inhibition of Cardiac Hypertrophy by Aromadendrin Through Down-Regulating NFAT and MAPKs Pathways.

Amphiregulin improves ventricular remodeling after myocardial infarction by modulating autophagy and apoptosis

The novel peptide athycaltide-1 attenuates Ang II-induced pathological myocardial hypertrophy by reducing ROS and inhibiting the activation of CaMKII and ERK1/2

High density lipoprotein downregulates angiotensin II type 1 receptor and inhibits angiotensin II-induced cardiac hypertrophy.

Citri reticulatae Pericarpium attenuates Ang II-induced pathological cardiac hypertrophy via upregulating peroxisome proliferator-activated receptors gamma

Angiotensin-(1-7) Attenuates Angiotensin II-induced Cardiac Hypertrophy Via a Sirt3-dependent Mechanism.

Andrographolide contributes to the attenuation of cardiac hypertrophy by suppressing endoplasmic reticulum stress

Angiotensin II prompts heart cell apoptosis via AT1 receptor-augmented phosphatase and tensin homolog and miR-320-3p functions to enhance suppression of the IGF1R-PI3K-AKT survival pathway

1,12-cyclic apelin-12 ameliorates Ang II and Apelin-13-induced cardiac hypertrophy by reducing mitochondrial oxidative damage

Up-regulation of P27kip1 Contributes to Nrf2-mediated Protection Against Angiotensin II-induced Cardiac Hypertrophy

Mir-34A Modulates Angiotensin II-induced Myocardial Hypertrophy by Direct Inhibition of ATG9A Expression and Autophagic Activity.

GW24-e2121 Adenosine Monophosphate-Activated Protein Kinase Attenuates Cardiomyocyte Hypertrophy Through Regulation of FOXO3a/MAFbx Signalling Pathway

HypERlnc attenuates angiotensin II‐induced cardiomyocyte hypertrophy via promoting SIRT1 SUMOylation‐mediated activation of PGC‐1α/PPARα pathway in AC16 cells

Epigallocatechin-3-gallate inhibits angiotensin II-induced cardiomyocyte hypertrophy via regulating Hippo signaling pathway in H9c2 rat cardiomyocytes.

ANGPTL8 is a negative regulator in pathological cardiac hypertrophy

A Disintegrin and Metalloprotease-22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway.

GW24-e3170 Angiotensin-(1-7) Downregulates Angiotensin II Type 1 Receptor and Inhibites Mechanical Stress-Induced Cardiomyocyte Autophagy

Inhibition of Endothelin Converting Enzyme-1 Activity or Expression Ameliorates Angiotensin Ii-Induced Myocardial Hypertrophy in Cultured Cardiomyocytes

Prostaglandin E1 Attenuates AngII-induced Cardiac Hypertrophy Via EP3 Receptor Activation and Netrin-1upregulation